New US guidelines recommend PrEP

CDC recommends pre-exposure prophylaxis for any non-monogamous gay man who has had condomless sex in the last six months

Gus Cairns
Published: 14 May 2014

The US Centers for Disease Control and Prevention (CDC) today released new guidelines recommending that pre-exposure prophylaxis (PrEP) should be considered for anyone HIV-negative who:

  • Is in an ongoing sexual relationship with a partner living with HIV.
  • Is a gay or bisexual man who has had sex without a condom or has been diagnosed with a sexually transmitted infection within the past six months, and is not in a mutually monogamous relationship with a partner who recently tested HIV negative.
  • Is a heterosexual man or woman who does not always use condoms when having sex with partners known to be at risk for HIV (for example, people who inject drugs or bisexual male partners of unknown HIV status), and is not in a mutually monogamous relationship with a partner who recently tested HIV negative.
  • Has, within the past six months, injected drugs and shared equipment or been in a treatment programme for injection drug use.

The US Food and Drug Administration (FDA) approved PrEP on 17 July 2012, but this only licensed Truvada (tenofovir plus emtricitabine) for use in HIV-negative people as a prevention measure; it did not make recommendations as to who should be considered for PrEP. 

The CDC issued previous guidelines in July 2011, well before the FDA approval, and only approximately 750 prescriptions for PrEP were made before FDA approval. Uptake has slowly increased since then but is still surprisingly low amongst gay men, with only 9% of physicians ever having prescribed it. The New York Times in an article today comments that the CDC's recommendations "could transform AIDS prevention in the United States" and that, if followed strictly, they would result in a 50-fold increase in Truvada prescriptions a year.    

"HIV infection is preventable, yet every year we see some 50,000 new HIV infections in the United States,” said CDC Director Tom Frieden. “PrEP, used along with other prevention strategies, has the potential to help at-risk individuals protect themselves and reduce new HIV infections in the United States."

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.